Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Gamida Cell Posts Updated Omidubicel Data In Blood Cancer Patients

Published 27/04/2022, 17:31
© Reuters.  Gamida Cell Posts Updated Omidubicel Data In Blood Cancer Patients
GMDAQ
-

  • Gamida Cell Ltd (NASDAQ: GMDA) announced that updated infection data on omidubicel compared to umbilical cord blood transplantation (UCB) was shared at the Transplantation & Cellular Therapy ASTCT and CIBMTR Tandem Meetings.
  • The data from a sub-study of the Phase 3 trial of omidubicel showed early and enhanced recovery of various immune cells, including circulatory dendritic cell subtypes, NK cells, and CD4+ T cells within the first 28 days.
  • Related: Gamida Cell Shares Jump On FDA Nod To Cell Therapy Trial In Blood Cancer Settings.
  • The recovery was sustained from Day 28 onwards, and such immune recovery was associated with lower rates of severe infection.
  • Gamida Cell initiated a rolling Biologics License Application (BLA) submission for omidubicel in Q1 of 2022 and is on track to complete the submission of all modules of the BLA in Q2 2022.
  • Price Action: GMDA shares are down 8.17% at $2.47 during the market session on the last check Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.